Canada-Approved Medicine
This monograph describes a medication approved for use in Canada by the Therapeutic Products Directorate, a division of Health Canadas Health Products and Food Branch. The medication is not approved by the United States Food and Drug Administration; however, a similar formulation carrying a different generic or brand name might be available in the US.
REMSContraindicated in:
Use Cautiously in:
All less than 1%
CNS: drowsiness, headache, vertigo.
GI: constipation, diarrhea, distention, dry mouth, epigastric pain/fullness, esophageal irritation, nausea.
Derm: rash.
Therapeutic Classification: anti irritable bowel syndrome agents
Pharmacologic Classification: calcium channel blockers
Absorption: Poorly absorbed (110%).
Distribution: Distributes selectively to digestive tract.
Protein Binding: 97%.
Metabolism/Excretion: Minimal enterohepatic cycling, eliminated almost entirely in feces. Some metabolism.
Half-life: 1.5 hr.